Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study: Uptake, Outcome, and Risk Factors for Treatment Failures in a Real-world Setting
Status: Recruiting
Location: See location...
Intervention Type: Biological, Drug
Study Type: Observational
SUMMARY
This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participant in the SHCS
• All SHCS participants initiating the CAB+RPV LA regimen
• All SHCS participants on SOC oral regimen
Locations
Other Locations
Switzerland
University Hospital Zurich
RECRUITING
Zurich
Contact Information
Primary
Dominique L Braun, MD
dominique.braun@usz.ch
0041442559196
Backup
Jessy J Duran Ramirez, MSc
jessy.duranramirez@usz.ch
00410446341911
Time Frame
Start Date: 2022-03-01
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 600
Treatments
Swiss HIV Cohort Study participants on CAB+RPV LA regimen
Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen
Swiss HIV Cohort Study participants on a standard of care oral regimen
Matched control population on a standard of care oral regimen
Related Therapeutic Areas
Sponsors
Collaborators: Swiss HIV Cohort Study
Leads: University of Zurich